Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects (TROIKA-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03776240
Recruitment Status : Completed
First Posted : December 14, 2018
Last Update Posted : August 30, 2019
Sponsor:
Information provided by (Responsible Party):
Prestige Biopharma Pte Ltd

Brief Summary:
The purpose of the study is to demonstrate demonstrate the pharmacokinetic (PK) similarity of HD201 to the European (EU) and American (US) reference products Herceptin, following a single i.v. infusion of 6 mg/kg in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: HD201 Drug: EU-Herceptin Drug: US-Herceptin Phase 1

Detailed Description:
This is a double-blind, randomised, parallel group study, where a total of 105 healthy adult male volunteers, ≥ 18 and ≤ 55 years of age, non-smoker, will be dosed; 35 subjects per treatment group, randomly assigned to one of the 3 treatment arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Screening
Official Title: A Phase I, Double-Blind, Randomised, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects
Actual Study Start Date : April 1, 2019
Actual Primary Completion Date : August 19, 2019
Actual Study Completion Date : August 19, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Trastuzumab

Arm Intervention/treatment
Experimental: HD201
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: HD201
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Other Name: Trastuzumab

Active Comparator: EU-licensed Herceptin
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: EU-Herceptin
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Other Name: Trastuzumab

Active Comparator: US-licensed Herceptin
Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Drug: US-Herceptin
Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Other Name: Trastuzumab




Primary Outcome Measures :
  1. Area under Curve (AUC, Pharmacokinetics) [ Time Frame: Up to day 54 ]
    Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin


Secondary Outcome Measures :
  1. Immunogenicity: Incidence of anti-herceptin antibodies [ Time Frame: 0 hour, Day 15, Day 29, Day 43, and Day 54 post-dose ]
    Incidence of anti-herceptin antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male, non-smoker (no use of tobacco products within 3 months prior to screening), ≥ 18 and ≤ 55 years of age, with BMI > 18.5 and < 30.0 kg/m2 and body weight ≥ 50.0 kg.
  2. Healthy as defined by:

    1. the absence of clinically significant illness and surgery within 4 weeks prior to dosing. Inclusion pre-dosing is at the discretion of the Principal Investigator.
    2. the absence of clinically significant history of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
    3. a LVEF within the normal range as measured by echocardiogram (ECHO) within 4 weeks prior to randomization.
    4. the absence of clinically significant history of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.
  3. Male subjects who are not vasectomized for at least 6 months, and who are sexually active with non-sterile female partner [sterile female partners include post-menopausal women (absence of menses for 12 months prior to drug administration) or women who have had a tubal ligation, hysterectomy, or bilateral oophorectomy (at least 6 months prior to drug administration)] must be willing to use one of the following acceptable contraceptive method throughout the study and for 90 days after the last study drug administration:

    1. simultaneous use of condom, and for the female partner hormonal contraceptives (used since at least 4 weeks) or intra-uterine contraceptive device (placed since at least 4 weeks);
    2. simultaneous use of male condom, and for the female partner, diaphragm with intravaginally applied spermicide.
  4. Male subjects, including men who have had vasectomy, with a pregnant partner must agree to use a condom throughout the study and for 90 days after the last study drug administration.
  5. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
  6. Capable of consent.

Exclusion Criteria:

f the following applies will be excluded from the study:

  1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
  2. Positive urine drug screen at screening.
  3. History of allergic reactions to trastuzumab, benzyl alcohol, murine proteins, or other related drugs.
  4. Any reason which, in the opinion of the Principal Investigator, would prevent the subject from participating in the study.
  5. Clinically significant ECG abnormalities (QTc >450 ms) and or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  6. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  7. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  8. Previous use of trastuzumab or another monoclonal antibody for a medical condition or in the context of another clinical trial.
  9. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
  10. Use of medication other than topical products without significant systemic absorption:

    1. prescription medication within 14 days prior to dose administration;
    2. over-the-counter products including natural health products (e.g. food supplements and herbal supplements) within 7 days prior to dosing, with the exception of the occasional use of acetaminophen (paracetamol - up to 2 g daily);
    3. a depot injection or an implant of any drug within 3 months prior to dose administration.
  11. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.
  12. Hemoglobin < 12.8 g/dL and hematocrit < 0.37 L/L at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03776240


Locations
Layout table for location information
Australia
Q Pharm
Brisbane, Australia
Sponsors and Collaborators
Prestige Biopharma Pte Ltd
Investigators
Layout table for investigator information
Study Chair: Lisa S Park Prestige Biopharma Pte Ltd

Layout table for additonal information
Responsible Party: Prestige Biopharma Pte Ltd
ClinicalTrials.gov Identifier: NCT03776240     History of Changes
Other Study ID Numbers: TROIKA-1
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: August 30, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Prestige Biopharma Pte Ltd:
randomized
double-blind
Additional relevant MeSH terms:
Layout table for MeSH terms
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents